Research progress in intratumoral microbiota: unlocking the potential of cancer immunotherapy
- 1Department of Critical Care Medicine, Youxian People’s Hospital , ,
Abstract
In recent years, intratumoral microbiota (ITM), a crucial component of the tumor microenvironment, have received increasing attention because of their role in cancer immunotherapy. ITM not only influence tumor initiation and progression but also modulate local and systemic immune responses, thereby affecting the efficacy of immune checkpoint inhibitors and other immunotherapeutic approaches. This review summarizes the compositional characteristics of ITM, their immunoregulatory mechanisms, and their effects on tumor metastasis and responsiveness to immunotherapy. Particular emphasis is placed on interactions between intratumoral microbiota and immune therapies across cancer types, highlighting potential therapeutic strategies that exploit these microbial influences. Furthermore, the review discusses current challenges in integrating intratumoral microbiota into immunotherapeutic paradigms and outlines future research directions. By providing a comprehensive overview of the role of ITM in cancer immunity, this review aims to support advances in precision oncology and foster novel approaches to enhance immunotherapy outcomes.
Related
- Temporal and therapeutic confounders in predicting efficacy of immunotherapy rechallenge via baseline intratumoral tertiary lymphoid structures.
- Editorial: Beyond conventional biomarkers: unlocking immunotherapy response through novel biomarkers or combinatorial approaches
- Intratumoral Immunotherapy-The Future of Treating Merkel Cell Carcinoma?
- Intratumoral Klebsiella pneumoniae drives metabolic-immune remodeling and immunotherapy resistance in bladder cancer
- Intratumoral microbiota stratifies glioma malignancy and patient survival through metabolic associations
BibTeX
@article{tian2026research,
title = {{Research progress in intratumoral microbiota: unlocking the potential of cancer immunotherapy}},
author = {Tian Tian and Min Chen},
journal = {Frontiers in immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1956198},
url = {https://europepmc.org/article/PMC/PMC13670171},
note = {CC BY},
}
RIS
TY - JOUR
TI - Research progress in intratumoral microbiota: unlocking the potential of cancer immunotherapy
AU - Tian Tian
AU - Min Chen
PY - 2026
DA - 2026/10/01
JO - Frontiers in immunology
DO - 10.3389/fimmu.2026.1956198
UR - https://europepmc.org/article/PMC/PMC13670171
AB - In recent years, intratumoral microbiota (ITM), a crucial component of the tumor microenvironment, have received increasing attention because of their role in cancer immunotherapy. ITM not only influence tumor initiation and progression but also modulate local and systemic immune responses, thereby affecting the efficacy of immune checkpoint inhibitors and other immunotherapeutic approaches. This review summarizes the compositional characteristics of ITM, their immunoregulatory mechanisms, and their effects on tumor metastasis and responsiveness to immunotherapy. Particular emphasis is placed on interactions between intratumoral microbiota and immune therapies across cancer types, highlighting potential therapeutic strategies that exploit these microbial influences. Furthermore, the review discusses current challenges in integrating intratumoral microbiota into immunotherapeutic paradigms and outlines future research directions. By providing a comprehensive overview of the role of ITM in cancer immunity, this review aims to support advances in precision oncology and foster novel approaches to enhance immunotherapy outcomes.
SN - 1664-3224
ER -